Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Protocols for Studies on Genetically Engineered Mouse Models in Prostate Cancer.

Armstrong CWD, Lyubomska O, LaBonte MJ, Waugh DJJ.

Methods Mol Biol. 2018;1786:195-206. doi: 10.1007/978-1-4939-7845-8_11.

PMID:
29786794
2.

The Unfolded Protein Response: A Novel Therapeutic Target for Poor Prognostic BRAF Mutant Colorectal Cancer.

Forsythe N, Refaat A, Javadi A, Khawaja H, Weir JA, Emam H, Allen WL, Burkamp F, Popovici V, Jithesh PV, Isella C, Labonte MJ, Mills IG, Johnston PG, Van Schaeybroeck S.

Mol Cancer Ther. 2018 Jun;17(6):1280-1290. doi: 10.1158/1535-7163.MCT-17-0603. Epub 2018 Feb 26.

PMID:
29483217
3.

A Phase II Biomarker-Embedded Study of Lapatinib plus Capecitabine as First-line Therapy in Patients with Advanced or Metastatic Gastric Cancer.

LaBonte MJ, Yang D, Zhang W, Wilson PM, Nagarwala YM, Koch KM, Briner C, Kaneko T, Rha SY, Gladkov O, Urba SG, Sakaeva D, Pishvaian MJ, Hsieh RK, Lee WP, Lenz HJ.

Mol Cancer Ther. 2016 Sep;15(9):2251-8. doi: 10.1158/1535-7163.MCT-15-0908. Epub 2016 Jun 20.

4.

PTEN deficiency promotes macrophage infiltration and hypersensitivity of prostate cancer to IAP antagonist/radiation combination therapy.

Armstrong CW, Maxwell PJ, Ong CW, Redmond KM, McCann C, Neisen J, Ward GA, Chessari G, Johnson C, Crawford NT, LaBonte MJ, Prise KM, Robson T, Salto-Tellez M, Longley DB, Waugh DJ.

Oncotarget. 2016 Feb 16;7(7):7885-98. doi: 10.18632/oncotarget.6955.

5.

Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.

Bohanes P, Yang D, Loupakis F, LaBonte MJ, Gerger A, Ning Y, Lenz C, Lenz F, Wakatsuki T, Zhang W, Benhaim L, El-Khoueiry A, El-Khoueiry R, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):226-34. doi: 10.1038/tpj.2014.66. Epub 2014 Dec 9.

PMID:
25487679
6.

Genetic variants of kinase suppressors of Ras (KSR1) to predict survival in patients with ERα-positive advanced breast cancer.

Benhaim L, Zhang W, Wakatsuki T, Yang D, Gerger A, Bohanes P, Paez D, Loupakis F, LaBonte MJ, Ning Y, El-Khoueiry R, Ladner R, Wilson P, Zhang H, Giamas G, Stebbing J, Lenz HJ.

Pharmacogenomics J. 2015 Jun;15(3):235-40. doi: 10.1038/tpj.2014.58. Epub 2014 Oct 7.

PMID:
25287073
7.

Role of cyclin polymorphisms in predicting outcome of 5-fluorouracil-based chemotherapy in colorectal cancer: one piece in a complex puzzle.

LaBonte MJ, Lenz HJ.

Pharmacogenomics. 2013 Nov;14(14):1671-4. doi: 10.2217/pgs.13.138. No abstract available.

8.

Plastin polymorphisms predict gender- and stage-specific colon cancer recurrence after adjuvant chemotherapy.

Ning Y, Gerger A, Zhang W, Hanna DL, Yang D, Winder T, Wakatsuki T, Labonte MJ, Stintzing S, Volz N, Sunakawa Y, Stremitzer S, El-Khoueiry R, Lenz HJ.

Mol Cancer Ther. 2014 Feb;13(2):528-39. doi: 10.1158/1535-7163.MCT-13-0646. Epub 2013 Oct 29.

9.

Molecular pathways: Estrogen pathway in colorectal cancer.

Barzi A, Lenz AM, Labonte MJ, Lenz HJ.

Clin Cancer Res. 2013 Nov 1;19(21):5842-8. doi: 10.1158/1078-0432.CCR-13-0325. Epub 2013 Aug 21. Review.

10.

Prognostic role of lemur tyrosine kinase-3 germline polymorphisms in adjuvant gastric cancer in Japan and the United States.

Wakatsuki T, LaBonte MJ, Bohanes PO, Zhang W, Yang D, Azuma M, Barzi A, Ning Y, Loupakis F, Saadat S, Volz N, Stintzing S, El-Khoueiry R, Koizumi W, Watanabe M, Shah M, Stebbing J, Giamas G, Lenz HJ.

Mol Cancer Ther. 2013 Oct;12(10):2261-72. doi: 10.1158/1535-7163.MCT-12-1134. Epub 2013 Aug 5.

11.

Association of common gene variants in the WNT/β-catenin pathway with colon cancer recurrence.

Páez D, Gerger A, Zhang W, Yang D, Labonte MJ, Benhanim L, Kahn M, Lenz F, Lenz C, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):142-50. doi: 10.1038/tpj.2013.20. Epub 2013 Jul 2.

PMID:
23817222
12.

Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy.

Benhaim L, Gerger A, Bohanes P, Paez D, Wakatsuki T, Yang D, Labonte MJ, Ning Y, El-Khoueiry R, Loupakis F, Zhang W, Laurent-Puig P, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):135-41. doi: 10.1038/tpj.2013.21. Epub 2013 Jun 11.

PMID:
23752739
13.

The cyclin D1 (CCND1) rs9344 G>A polymorphism predicts clinical outcome in colon cancer patients treated with adjuvant 5-FU-based chemotherapy.

Absenger G, Benhaim L, Szkandera J, Zhang W, Yang D, Labonte MJ, Pichler M, Stotz M, Samonigg H, Renner W, Gerger A, Lenz HJ.

Pharmacogenomics J. 2014 Apr;14(2):130-4. doi: 10.1038/tpj.2013.15. Epub 2013 Apr 9.

PMID:
23567490
14.

Sustained inhibition of deacetylases is required for the antitumor activity of the histone deactylase inhibitors panobinostat and vorinostat in models of colorectal cancer.

Wilson PM, Labonte MJ, Martin SC, Kuwahara ST, El-Khoueiry A, Lenz HJ, Ladner RD.

Invest New Drugs. 2013 Aug;31(4):845-57. doi: 10.1007/s10637-012-9914-7. Epub 2013 Jan 9.

PMID:
23299388
15.

Assessing the in vivo efficacy of biologic antiangiogenic therapies.

Wilson PM, LaBonte MJ, Lenz HJ.

Cancer Chemother Pharmacol. 2013 Jan;71(1):1-12. doi: 10.1007/s00280-012-1978-8. Epub 2012 Oct 9. Review.

PMID:
23053262
16.

Selecting the best targeted agent in first-line treatment of unresectable liver metastases from colorectal cancer: does the bench have the answers?

Benhaim L, Loupakis F, Labonte MJ, Lenz HJ.

J Hepatobiliary Pancreat Sci. 2012 Sep;19(5):528-35. doi: 10.1007/s00534-012-0526-6. Review.

PMID:
22735932
17.

Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis.

Lee YS, Choi I, Ning Y, Kim NY, Khatchadourian V, Yang D, Chung HK, Choi D, LaBonte MJ, Ladner RD, Nagulapalli Venkata KC, Rosenberg DO, Petasis NA, Lenz HJ, Hong YK.

Br J Cancer. 2012 May 22;106(11):1833-41. doi: 10.1038/bjc.2012.177.

18.

Influence of sex on the survival of patients with esophageal cancer.

Bohanes P, Yang D, Chhibar RS, Labonte MJ, Winder T, Ning Y, Gerger A, Benhaim L, Paez D, Wakatsuki T, Loupakis F, El-Khoueiry R, Zhang W, Lenz HJ.

J Clin Oncol. 2012 Jun 20;30(18):2265-72. doi: 10.1200/JCO.2011.38.8751. Epub 2012 May 14.

19.

The CXCR2 antagonist, SCH-527123, shows antitumor activity and sensitizes cells to oxaliplatin in preclinical colon cancer models.

Ning Y, Labonte MJ, Zhang W, Bohanes PO, Gerger A, Yang D, Benhaim L, Paez D, Rosenberg DO, Nagulapalli Venkata KC, Louie SG, Petasis NA, Ladner RD, Lenz HJ.

Mol Cancer Ther. 2012 Jun;11(6):1353-64. doi: 10.1158/1535-7163.MCT-11-0915. Epub 2012 Mar 5.

20.

Pancreatic cancer: medical management (novel chemotherapeutics).

Páez D, Labonte MJ, Lenz HJ.

Gastroenterol Clin North Am. 2012 Mar;41(1):189-209. doi: 10.1016/j.gtc.2011.12.004. Epub 2012 Jan 15. Review.

PMID:
22341258
21.

"HER majesty's a pretty nice girl but she changes from day to day".

Bohanes P, Loupakis F, Labonte MJ, Wakatsuki T, Lenz HJ.

J Clin Oncol. 2012 Feb 1;30(4):465-6; author reply 466-7. doi: 10.1200/JCO.2011.39.4098. Epub 2011 Dec 27. No abstract available.

PMID:
22203763
22.

Pharmacogenomics and metastatic colorectal cancer: current knowledge and perspectives.

Benhaim L, Labonte MJ, Lenz HJ.

Scand J Gastroenterol. 2012 Mar;47(3):325-39. doi: 10.3109/00365521.2012.640832. Epub 2011 Dec 19. Review.

PMID:
22182673
23.

Inhibition of dUTPase induces synthetic lethality with thymidylate synthase-targeted therapies in non-small cell lung cancer.

Wilson PM, LaBonte MJ, Lenz HJ, Mack PC, Ladner RD.

Mol Cancer Ther. 2012 Mar;11(3):616-28. doi: 10.1158/1535-7163.MCT-11-0781. Epub 2011 Dec 15.

24.

Cancer dormancy: a model of early dissemination and late cancer recurrence.

Páez D, Labonte MJ, Bohanes P, Zhang W, Benhanim L, Ning Y, Wakatsuki T, Loupakis F, Lenz HJ.

Clin Cancer Res. 2012 Feb 1;18(3):645-53. doi: 10.1158/1078-0432.CCR-11-2186. Epub 2011 Dec 9. Review.

25.

The Cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer.

Labonte MJ, Wilson PM, Yang D, Zhang W, Ladner RD, Ning Y, Gerger A, Bohanes PO, Benhaim L, El-Khoueiry R, El-Khoueiry A, Lenz HJ.

Ann Oncol. 2012 Jun;23(6):1455-64. doi: 10.1093/annonc/mdr445. Epub 2011 Oct 11.

26.

Common cancer stem cell gene variants predict colon cancer recurrence.

Gerger A, Zhang W, Yang D, Bohanes P, Ning Y, Winder T, LaBonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, El-Khoueiry A, Kahn M, Lenz HJ.

Clin Cancer Res. 2011 Nov 1;17(21):6934-43. doi: 10.1158/1078-0432.CCR-11-1180. Epub 2011 Sep 14.

27.

A review of excision repair cross-complementation group 1 in colorectal cancer.

Bohanes P, Labonte MJ, Lenz HJ.

Clin Colorectal Cancer. 2011 Sep;10(3):157-64. doi: 10.1016/j.clcc.2011.03.024. Epub 2011 Apr 28. Review.

PMID:
21855036
28.

Predictive molecular classifiers in colorectal cancer.

Bohanes P, LaBonte MJ, Winder T, Lenz HJ.

Semin Oncol. 2011 Aug;38(4):576-87. doi: 10.1053/j.seminoncol.2011.05.012. Review.

PMID:
21810517
29.

Pharmacogenetic angiogenesis profiling for first-line Bevacizumab plus oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer.

Gerger A, El-Khoueiry A, Zhang W, Yang D, Singh H, Bohanes P, Ning Y, Winder T, Labonte MJ, Wilson PM, Benhaim L, Paez D, El-Khoueiry R, Absenger G, Lenz HJ.

Clin Cancer Res. 2011 Sep 1;17(17):5783-92. doi: 10.1158/1078-0432.CCR-11-1115. Epub 2011 Jul 26.

30.

EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.

Hu-Lieskovan S, Vallbohmer D, Zhang W, Yang D, Pohl A, Labonte MJ, Grimminger PP, Hölscher AH, Semrau R, Arnold D, Dellas K, Debucquoy A, Haustermans K, Machiels JP, Sempoux C, Rödel C, Bracko M, Velenik V, Lenz HJ.

Clin Cancer Res. 2011 Aug 1;17(15):5161-9. doi: 10.1158/1078-0432.CCR-10-2666. Epub 2011 Jun 14.

31.

A novel fluorescence-based assay for the rapid detection and quantification of cellular deoxyribonucleoside triphosphates.

Wilson PM, Labonte MJ, Russell J, Louie S, Ghobrial AA, Ladner RD.

Nucleic Acids Res. 2011 Sep 1;39(17):e112. doi: 10.1093/nar/gkr350. Epub 2011 May 16.

32.

A coactivator role of CARM1 in the dysregulation of β-catenin activity in colorectal cancer cell growth and gene expression.

Ou CY, LaBonte MJ, Manegold PC, So AY, Ianculescu I, Gerke DS, Yamamoto KR, Ladner RD, Kahn M, Kim JH, Stallcup MR.

Mol Cancer Res. 2011 May;9(5):660-70. doi: 10.1158/1541-7786.MCR-10-0223. Epub 2011 Apr 8.

33.

The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.

LaBonte MJ, Wilson PM, Fazzone W, Russell J, Louie SG, El-Khoueiry A, Lenz HJ, Ladner RD.

Cancer Res. 2011 May 15;71(10):3635-48. doi: 10.1158/0008-5472.CAN-10-2430. Epub 2011 Apr 4.

34.

KRAS let-7 LCS6 SNP predicts cetuximab efficacy in KRASwt metastatic colorectal cancer patients: Does treatment combination partner matter?

Zhang W, Labonte MJ, Lenz HJ.

Ann Oncol. 2011 Feb;22(2):484-5. doi: 10.1093/annonc/mdq704. Epub 2011 Jan 28. No abstract available.

PMID:
21278223
35.

Interleukin-8 is associated with proliferation, migration, angiogenesis and chemosensitivity in vitro and in vivo in colon cancer cell line models.

Ning Y, Manegold PC, Hong YK, Zhang W, Pohl A, Lurje G, Winder T, Yang D, LaBonte MJ, Wilson PM, Ladner RD, Lenz HJ.

Int J Cancer. 2011 May 1;128(9):2038-49. doi: 10.1002/ijc.25562.

36.

A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy.

Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, Lurje G, Labonte MJ, Wilson PM, Gordon MA, Hu-Lieskovan S, Mauro DJ, Langer C, Rowinsky EK, Lenz HJ.

Ann Oncol. 2011 Jan;22(1):104-9. doi: 10.1093/annonc/mdq315. Epub 2010 Jul 5.

PMID:
20603437
37.

Molecular markers in the treatment of metastatic colorectal cancer.

Wilson PM, Labonte MJ, Lenz HJ.

Cancer J. 2010 May-Jun;16(3):262-72. doi: 10.1097/PPO.0b013e3181e07738. Review.

PMID:
20526105
38.

A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy.

Wilson PM, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte MJ, Groshen S, Yang D, Danenberg KD, Cole S, Kornacki M, Ladner RD, Lenz HJ.

Cancer Chemother Pharmacol. 2010 Apr;65(5):979-88. doi: 10.1007/s00280-009-1236-x.

PMID:
20062993
39.

DNA microarray profiling of genes differentially regulated by the histone deacetylase inhibitors vorinostat and LBH589 in colon cancer cell lines.

LaBonte MJ, Wilson PM, Fazzone W, Groshen S, Lenz HJ, Ladner RD.

BMC Med Genomics. 2009 Nov 30;2:67. doi: 10.1186/1755-8794-2-67.

40.

The dual EGFR/HER-2 tyrosine kinase inhibitor lapatinib sensitizes colon and gastric cancer cells to the irinotecan active metabolite SN-38.

LaBonte MJ, Manegold PC, Wilson PM, Fazzone W, Louie SG, Lenz HJ, Ladner RD.

Int J Cancer. 2009 Dec 15;125(12):2957-69. doi: 10.1002/ijc.24658.

41.

Histone deacetylase inhibitors suppress thymidylate synthase gene expression and synergize with the fluoropyrimidines in colon cancer cells.

Fazzone W, Wilson PM, Labonte MJ, Lenz HJ, Ladner RD.

Int J Cancer. 2009 Jul 15;125(2):463-73. doi: 10.1002/ijc.24403.

42.

Regulation of human dUTPase gene expression and p53-mediated transcriptional repression in response to oxaliplatin-induced DNA damage.

Wilson PM, Fazzone W, LaBonte MJ, Lenz HJ, Ladner RD.

Nucleic Acids Res. 2009 Jan;37(1):78-95. doi: 10.1093/nar/gkn910. Epub 2008 Nov 16.

43.

Novel opportunities for thymidylate metabolism as a therapeutic target.

Wilson PM, Fazzone W, LaBonte MJ, Deng J, Neamati N, Ladner RD.

Mol Cancer Ther. 2008 Sep;7(9):3029-37. doi: 10.1158/1535-7163.MCT-08-0280.

44.

Problem-based learning in a health sciences librarianship course.

Dimitroff A, Ancona AM, Beman SB, Dodge AM, Hutchinson KL, LaBonte MJ, Mays TL, Simon DT.

Bull Med Libr Assoc. 1998 Jul;86(3):340-5.

Supplemental Content

Loading ...
Support Center